RespireRx Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 2.1 million compared to USD 3.14 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.04 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0009 USD | -10.00% | +12.50% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 775K | |
-2.90% | 102B | |
+1.49% | 96.09B | |
+2.13% | 22.28B | |
-17.07% | 21.4B | |
-9.03% | 18.14B | |
-39.98% | 17.02B | |
-14.17% | 16.09B | |
+6.12% | 13.83B | |
+33.19% | 11.97B |
- Stock Market
- Equities
- RSPI Stock
- News RespireRx Pharmaceuticals Inc.
- RespireRx Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022